Today: 12 March 2026
Subscribe
Browse Category

NYSE:JNJ 23 January 2026 - 4 February 2026

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
··
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson shares rose 0.4% to $221.01 Monday as investors awaited the Federal Reserve’s Jan. 28 decision and major tech earnings. The company projected 2026 adjusted earnings per share of $11.43–$11.63 and sales up to $101 billion. A court-appointed special master recommended allowing expert testimony that J&J’s talc caused ovarian cancer, raising the risk of federal trials. J&J denies the allegations.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson shares rose 0.76% to $220.14 at Friday’s close, outpacing other major pharma stocks. The company reaffirmed its 2026 sales and profit targets after posting Q4 sales of $24.6 billion and adjusted EPS of $2.46. Legal risks remain as a special master recommended expert testimony in federal talc lawsuits. Investors await the Federal Reserve’s rate decision on Wednesday.
25 January 2026
··
Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson shares closed Friday up 0.8% at $220.14 after TD Cowen and Citi raised price targets to $250, citing strong 2026 guidance. Q4 2025 sales reached $24.6 billion with adjusted EPS at $2.46. A court special master recommended allowing expert testimony in federal talc lawsuits. The company declared a $1.30 quarterly dividend, payable March 10.
24 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
1 2 3 4 … 8

Stock Market Today

  • Sugar Prices Slip After Reaching Two-Month Peak Amid Surplus Concerns
    March 12, 2026, 4:13 AM EDT. Sugar prices declined on Wednesday, with May New York world sugar down 0.90% and May London ICE white sugar falling 1.15%. The retreat followed a two-month high on Monday and was driven by long liquidation and a slightly stronger dollar. Despite a 5% rally in oil prices, which often supports sugar by boosting ethanol production and reducing sugar supply, concerns about a persistent global sugar surplus weighed on the market. Multiple analysts and the International Sugar Organization project sugar surpluses ranging from 1.22 to 8.3 million metric tons for 2025-27, driven by increased output in countries like India, Thailand, and Pakistan. India, the world's second-largest sugar producer, raised export quotas amid higher production, pressuring prices further.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 12.03.2026

12 March 2026
LIVEMarkets rolling coverageStarted: March 12, 2026, 12:00 AM EDTUpdated: March 12, 2026, 4:13 AM EDT Sugar Prices Slip After Reaching Two-Month Peak Amid Surplus Concerns March 12, 2026, 4:13 AM EDT. Sugar prices declined on Wednesday, with May New York world sugar down 0.90% and May London ICE white sugar falling 1.15%. The retreat followed a two-month high on Monday and was driven by long liquidation and a slightly stronger dollar. Despite a 5% rally in oil prices, which often supports sugar by boosting ethanol production and reducing sugar supply, concerns about a persistent global sugar surplus weighed on the
XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

11 March 2026
XRP traded near $1.40, down 1.4% Wednesday, after Ripple announced plans to acquire BC Payments Australia to secure an Australian Financial Services Licence. The move comes as Australia tightens licensing rules for digital-asset firms. Broader crypto markets remained cautious amid concerns over oil prices, Iran, and U.S. inflation. Ripple’s deal is pending completion.
Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

11 March 2026
European natural gas prices held near 48 euros per megawatt hour Wednesday as Shell declared force majeure on Qatari LNG cargoes, with disruptions expected to hit from April. Asia is bidding up for replacement fuel, while Brussels considers subsidies or a price cap. LNG Canada increased shipments, but analysts warn Europe’s gas storage could end March far below average if Qatari supply issues persist.
Go toTop